Korea Investment CORP Cuts Stock Position in CVS Health Corporation $CVS

Key Points

• Korea Investment CORP trimmed its position in CVS by 10.2% in Q3, selling 92,211 shares and retaining 811,351 shares worth about $61.17 million (≈0.06% ownership).
• CVS launched Health100, an AI‑native health‑tech platform built with Google Cloud that management says could unify payer/provider/pharmacy data to drive personalized engagement and become a long‑term revenue and margin lever amid broad media coverage.
• Regulatory risk in Tennessee — a proposed bill would bar firms from owning both retail pharmacies and PBMs and could force CVS to close all 134 state locations, posing a material operational and sentiment risk.

Korea Investment CORP trimmed its position in CVS Health Corporation (NYSE:CVS - Free Report) by 10.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 811,351 shares of the pharmacy operator's stock after selling 92,211 shares during the period. Korea Investment CORP owned approximately 0.06% of CVS Health worth $61,168,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CVS. Harbor Capital Advisors Inc. raised its position in CVS Health by 72.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator's stock worth $26,000 after buying an additional 142 shares during the last quarter. Corundum Trust Company INC purchased a new stake in shares of CVS Health in the third quarter valued at about $29,000. Front Row Advisors LLC increased its stake in shares of CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator's stock worth $31,000 after acquiring an additional 371 shares during the period. SOA Wealth Advisors LLC. raised its holdings in CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock worth $37,000 after purchasing an additional 131 shares in the last quarter. Finally, Twin Peaks Wealth Advisors LLC purchased a new position in CVS Health during the second quarter worth about $36,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native health‑tech subsidiary and consumer engagement platform built with Google Cloud. Management says the platform will unify data across payers, providers and pharmacies to drive personalized engagement and better outcomes — a potential long‑term revenue and margin lever if adoption scales. CVS taps Google Cloud to roll out AI-powered health platform
• Positive Sentiment: Broad media and trade coverage highlights the Google Cloud tie‑up and Health100 rollout, increasing visibility for CVS as a tech-enabled healthcare integrator — this can support multiple revenue streams (retail, PBM, value-based care) over time. CVS Health And Google Launch AI Business To ‘Personalize Healthcare'
• Positive Sentiment: Analyst and long‑term bulls point to margin recovery and FY2026 guidance (CVS set EPS guidance ~5.94–6.14) plus a recent quarterly beat — supporting the thesis that Medicare Advantage margin improvement and Health100 monetization could drive sizable upside over 12–24 months. CVS Health: Stop Catastrophizing, Start Believing - Here's Why
• Neutral Sentiment: Market commentary questions whether recent gains already price in recovery — some pieces analyze valuation and one‑year returns, useful for timing but not a direct catalyst. Is CVS Health (CVS) Still Attractive After A 27% One Year Share Price Gain
• Negative Sentiment: Regulatory risk in Tennessee: a proposed bill would bar companies from owning both retail pharmacies and PBMs, and CVS warned it could close all 134 locations in the state if the law passes — an example of state‑level regulatory risks that could hit revenue, footprint and investor sentiment. CVS warns bill would force shutdown of 134 pharmacies in this state
• Negative Sentiment: Wolfe Research trimmed its price target on CVS, a modest negative for near‑term sentiment even though the firm remains focused on longer‑term fundamentals. Wolfe Research Cuts CVS Health NYSE: CVS Price Target to $97.00

CVS Health Stock Down 1.0%

CVS opened at $77.91 on Monday. The firm has a market cap of $99.12 billion, a P/E ratio of 56.46, a PEG ratio of 0.81 and a beta of 0.49. The business's fifty day simple moving average is $78.49 and its 200 day simple moving average is $77.65. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. During the same quarter in the previous year, the company posted $1.19 EPS. The firm's revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. CVS Health's dividend payout ratio is presently 192.75%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CVS. TD Cowen lifted their price objective on CVS Health from $100.00 to $105.00 and gave the company a "buy" rating in a report on Wednesday, December 10th. Leerink Partners reissued an "outperform" rating and set a $98.00 target price on shares of CVS Health in a research note on Thursday. Cantor Fitzgerald restated an "overweight" rating on shares of CVS Health in a research note on Wednesday, December 10th. The Goldman Sachs Group upped their price objective on CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. Finally, Barclays raised their target price on CVS Health from $87.00 to $93.00 and gave the company an "overweight" rating in a report on Wednesday, December 10th. Nineteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.91.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.